- Home
- BIRD vs LITS Comparison
BIRD vs LITS Comparison
Compare BIRD & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIRD | LITS |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 25.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | BIRD | LITS |
|---|---|---|
| Price | $2.49 | $0.89 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 304.0K | 141.2K |
| Earning Date | 05-07-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $152,466,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $35.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.15 | $0.69 |
| 52 Week High | $24.31 | $3.03 |
Technical Indicators
Market Signals| Indicator | BIRD | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 38.80 | 37.93 |
| Support Level | $2.45 | $0.79 |
| Resistance Level | $3.36 | $1.25 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 42.25 | 12.37 |
Price Performance
Historical ComparisonAbout BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.